What is the official website of EVERSANA ENGAGE ?

The official website of EVERSANA ENGAGE is http://eversanaengage.com.

What is EVERSANA ENGAGE's cybersecurity risk score?

EVERSANA ENGAGE has an AI-generated cybersecurity risk score of 750 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has EVERSANA ENGAGE experienced?

According to Rankiteo, EVERSANA ENGAGE currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has EVERSANA ENGAGE been affected by any supply chain cyber incidents ?

According to Rankiteo, EVERSANA ENGAGE has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does EVERSANA ENGAGE have SOC 2 Type 1 certification ?

According to Rankiteo, EVERSANA ENGAGE is not certified under SOC 2 Type 1.

Does EVERSANA ENGAGE have SOC 2 Type 2 certification ?

According to Rankiteo, EVERSANA ENGAGE does not hold a SOC 2 Type 2 certification.

Does EVERSANA ENGAGE comply with GDPR ?

According to Rankiteo, EVERSANA ENGAGE is not listed as GDPR compliant.

Does EVERSANA ENGAGE have PCI DSS certification ?

According to Rankiteo, EVERSANA ENGAGE does not currently maintain PCI DSS compliance.

Does EVERSANA ENGAGE comply with HIPAA ?

According to Rankiteo, EVERSANA ENGAGE is not compliant with HIPAA regulations.

Does EVERSANA ENGAGE have ISO 27001 certification ?

According to Rankiteo,EVERSANA ENGAGE is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does EVERSANA ENGAGE operate in ?

EVERSANA ENGAGE operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does EVERSANA ENGAGE have ?

EVERSANA ENGAGE employs approximately 13 people worldwide.

Does EVERSANA ENGAGE own any subsidiaries ?

EVERSANA ENGAGE presently has no subsidiaries across any sectors.

How many LinkedIn followers does EVERSANA ENGAGE have ?

EVERSANA ENGAGE's official LinkedIn profile has approximately 3,183 followers.

What is the NAICS classification code for EVERSANA ENGAGE ?

EVERSANA ENGAGE is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does EVERSANA ENGAGE have a Crunchbase profile ?

No, EVERSANA ENGAGE does not have a profile on Crunchbase.

Does EVERSANA ENGAGE have a LinkedIn profile ?

Yes, EVERSANA ENGAGE maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/eversana-engage.

How many cybersecurity incidents has EVERSANA ENGAGE experienced ?

As of June 24, 2026, Rankiteo reports that EVERSANA ENGAGE has experienced 1 cybersecurity incidents.

How many peer or competitor companies does EVERSANA ENGAGE have ?

EVERSANA ENGAGE has an estimated 5,695 peer or competitor companies worldwide.

What types of cybersecurity incidents has EVERSANA ENGAGE faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

EVERSANA ENGAGE

Boost Score +25 with badge (5 left)

750

/1000

Fair

775

/1000

Fair

EVERSANA ENGAGE Vendor Cyber Rating & Cyber Score

eversanaengage.com

Add Your Compliance Badge

EVERSANA ENGAGE is a full-service healthcare marketing agency serving the biotechnology and pharmaceutical industries. As experts in patient engagement, healthcare professional marketing, and market access, we optimize communications to enhance experiences and improve outcomes. Today’s multistakeholder era of healthcare demands a strategic and creative partner who’s adept at making connections among patients, providers, and payers. That’s where we live, breathe, and excel. EVERSANA ENGAGE has more than 170 professionals around the country and across the pond. In addition to the experts and experience within EVERSANA ENGAGE, we are a part of EVERSANA––the leading independent provider of global services to the life sciences industry. We

EVERSANA ENGAGE A.I CyberSecurity Scoring

Scoring History

EVERSANA ENGAGE

EVERSANA ENGAGE CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

EVERSANA ENGAGE

Breach

4/2019

EVE238072625

Loading…

A.I.

EVERSANA ENGAGE Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for EVERSANA ENGAGE

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for EVERSANA ENGAGE in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for EVERSANA ENGAGE in 2026.

Incident Types EVERSANA ENGAGE vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for EVERSANA ENGAGE in 2026.

Incident History - EVERSANA ENGAGE (X = Date, Y = Severity)

Loading…

SUBSIDIARY

EVERSANA ENGAGE Subsidiaries

EVERSANA ENGAGE

Pharmaceutical Manufacturing

Website: http://eversanaengage.com

Company Size: 13

EVERSANAPharmaceutical Manufacturing

NAVLIN Price & Access DataPharmaceutical Manufacturing

EVERSANA INTOUCHAdvertising Services

Alamo Pharma ServicesPharmaceutical Manufacturing

Seeker Health by EVERSANAPharmaceutical Manufacturing

NAVLIN by EVERSANAPharmaceutical Manufacturing

Loading…

EVERSANA ENGAGE Similar Companies

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Loading…

NEWS

EVERSANA ENGAGE CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-54236

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). Prior to 0.23.1rc0, the fix for CVE-2026-22778, which introduced a sanitize_message helper that strips object-repr memory addresses from error messages before they reach the client, is incomplete: several response paths echo str(exc) directly to clients without calling sanitize_message. The unsanitized sites include the Anthropic API router in vllm/entrypoints/anthropic/api_router.py (the POST /v1/messages and POST /v1/messages/count_tokens handlers), the Server-Sent Events streaming converter in vllm/entrypoints/anthropic/serving.py, and the realtime speech-to-text WebSocket in vllm/entrypoints/speech_to_text/realtime/connection.py. These paths catch the exception inside the route coroutine and construct the JSONResponse themselves, bypassing the sanitizing global FastAPI exception handler, and WebSocket frames do not traverse that handler chain at all. Using the same primitive as the parent issue, an unauthenticated attacker can send malformed image bytes through the Anthropic Messages API image content parts so that PIL.Image.open raises an UnidentifiedImageError whose message contains the BytesIO object repr, leaking the heap memory address verbatim in the error.message field of the response body. This vulnerability is fixed in 0.23.1rc0.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-54235

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). Prior to 0.23.1rc0, ll temperature validation gates use comparison operators (<, >), which silently evaluate to False for NaN and for positive Infinity in Python's IEEE 754 float semantics. Both values pass every guard and propagate to GPU sampling kernels, where they produce undefined behavior or CUDA errors that can crash the inference worker. This vulnerability is fixed in 0.23.1rc0.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-54233

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). Prior to 0.23.1rc0, vLLM's /v1/audio/transcriptions endpoint limits compressed upload size but not decoded PCM output. A 25MB OPUS file expands to ~14.9GB of float32 PCM at decode time. This vulnerability is fixed in 0.23.1rc0.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-54232

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). Prior to 0.22.1, the vLLM Dockerfile is vulnerable to a dependency confusion attack through the flashinfer-jit-cache package. The package is installed from a custom index (flashinfer.ai/whl/) using --extra-index-url, but the package name was not registered on PyPI, and UV_INDEX_STRATEGY="unsafe-best-match" is set globally. An attacker who registers flashinfer-jit-cache on PyPI with version 0.6.11.post2 can execute arbitrary code as root during the Docker build and backdoor every resulting container image, enabling exfiltration of all user prompts, API credentials, and model data from production vLLM deployments This vulnerability is fixed in 0.22.1.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://github.com/vllm-project/vllm/security/advisories/GHSA-jrf6-vqxq-pjv2

CVE-2026-53923

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). From 0.5.5 until 0.23.1rc0, integer truncation of tensor dimensions in vLLM's GGUF dequantize kernels (csrc/quantization/gguf/gguf_kernel.cu) causes partial tensor processing. The output tensor is allocated at full size via torch::empty (uninitialized memory), but the dequantize CUDA kernel processes only a truncated number of elements. The unfilled portion of the output tensor retains whatever was previously in GPU memory. In multi-tenant inference deployments, this residual GPU memory may contain tensor data from other users' inference requests, constituting information disclosure. This vulnerability is fixed in 0.23.1rc0.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: )

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…